WO2014006529A3 - Compositions and methods for the treatment of moderate to severe pain - Google Patents

Compositions and methods for the treatment of moderate to severe pain Download PDF

Info

Publication number
WO2014006529A3
WO2014006529A3 PCT/IB2013/055146 IB2013055146W WO2014006529A3 WO 2014006529 A3 WO2014006529 A3 WO 2014006529A3 IB 2013055146 W IB2013055146 W IB 2013055146W WO 2014006529 A3 WO2014006529 A3 WO 2014006529A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
compositions
treatment
methods
moderate
Prior art date
Application number
PCT/IB2013/055146
Other languages
French (fr)
Other versions
WO2014006529A2 (en
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Priority to CA2873018A priority Critical patent/CA2873018A1/en
Priority to SG11201407328TA priority patent/SG11201407328TA/en
Priority to AU2013285126A priority patent/AU2013285126A1/en
Priority to JP2015519430A priority patent/JP2015527309A/en
Priority to EP13813543.9A priority patent/EP2870130A4/en
Priority to CN201380030651.9A priority patent/CN104583162A/en
Publication of WO2014006529A2 publication Critical patent/WO2014006529A2/en
Publication of WO2014006529A3 publication Critical patent/WO2014006529A3/en
Priority to ZA2014/08057A priority patent/ZA201408057B/en
Priority to US14/827,487 priority patent/US9403793B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains

Abstract

The invention relates to the compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof The pharmaceutical compositions comprising art effective amount of compounds of formula Ϊ; and methods for treating or preventing moderate to severe pain, may he formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenieral adminisiration, syrup, or injection. Such compositions may be used to treatment of muscle pain, spasticity, neuropathic pain, fibromyalgia, postoperative pain,.muscle spasticity, headache, chronic pain, sub-chronic pain and local pain.
PCT/IB2013/055146 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain WO2014006529A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2873018A CA2873018A1 (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain
SG11201407328TA SG11201407328TA (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain
AU2013285126A AU2013285126A1 (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain
JP2015519430A JP2015527309A (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain
EP13813543.9A EP2870130A4 (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain
CN201380030651.9A CN104583162A (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain
ZA2014/08057A ZA201408057B (en) 2012-07-03 2014-11-04 Compositions and methods for the treatment of moderate to severe pain
US14/827,487 US9403793B2 (en) 2012-07-03 2015-08-17 Compositions and methods for the treatment of moderate to severe pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2682CH2012 2012-07-03
IN2682/CHE/2012 2012-07-03

Publications (2)

Publication Number Publication Date
WO2014006529A2 WO2014006529A2 (en) 2014-01-09
WO2014006529A3 true WO2014006529A3 (en) 2014-04-24

Family

ID=54188020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/055146 WO2014006529A2 (en) 2012-07-03 2013-06-23 Compositions and methods for the treatment of moderate to severe pain

Country Status (8)

Country Link
EP (1) EP2870130A4 (en)
JP (1) JP2015527309A (en)
CN (1) CN104583162A (en)
AU (1) AU2013285126A1 (en)
CA (1) CA2873018A1 (en)
SG (1) SG11201407328TA (en)
WO (1) WO2014006529A2 (en)
ZA (1) ZA201408057B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407307YA (en) * 2012-05-07 2014-12-30 Cellix Bio Private Ltd Prodrugs of anti-platelet agents
WO2016046674A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of moderate to severe pain
CN105037241B (en) * 2015-06-19 2018-02-23 上海上药新亚药业有限公司 The synthesis technique of 1 (2,6 dichlorophenyl) 2 indolones
CN111116391A (en) * 2019-12-17 2020-05-08 浙江工业大学 Preparation method of sodium 2- [ (2, 6-dichlorophenyl) amino ] phenylacetate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000167A2 (en) * 2000-06-23 2002-01-03 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
CN101186583A (en) * 2007-12-20 2008-05-28 吉林大学 Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application
WO2010115252A1 (en) * 2009-04-06 2010-10-14 Ems S.A. PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-α MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137301C (en) * 1966-03-30
AU514991B2 (en) * 1976-05-26 1981-03-12 Commonwealth Of Australia, The Pharmaceutical compositions containing antiinflammatory analgesic compounds
LU78106A1 (en) * 1977-05-11 1979-05-23 Ciba Geigy Ag PROCESS FOR PREPARING NEW SUBSTITUTED PHENYL ACID AMIDE COMPOUNDS
JPS5412340A (en) * 1977-06-27 1979-01-30 Daito Koeki Process for preparing phenylacetate derivative
NL8602767A (en) * 1986-10-31 1988-05-16 Gantax Nv ORGANIC ACID ANHYDRIDE, AND A PHARMACEUTICAL PREPARATION BASED ON A PRODRUG.
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JPH1143467A (en) * 1997-05-14 1999-02-16 Ikeda Mohandou:Kk Fatty acid glyceride derivative and glyceride derivative, and their production
US8765815B2 (en) * 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20090082450A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched diclofenac
US9525998B2 (en) * 2012-01-06 2016-12-20 Qualcomm Incorporated Wireless display with multiscreen service
CN107257275B (en) * 2012-01-27 2021-03-16 交互数字专利控股公司 Method for ePDCCH performed by WTRU, search space monitoring method and UE
SG11201407300VA (en) * 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
SG11201407307YA (en) * 2012-05-07 2014-12-30 Cellix Bio Private Ltd Prodrugs of anti-platelet agents
EP2882427A2 (en) * 2012-05-08 2015-06-17 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
JP2015526385A (en) * 2012-05-08 2015-09-10 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of epilepsy
AU2013257708A1 (en) * 2012-05-08 2014-12-04 Cellixbio Private Limited Compositions and methods for the treatment of diabetes
CA2872978A1 (en) * 2012-05-08 2013-11-14 Cellixbio Private Limited Compositions and methods for suppression of carbonic anhydrase activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000167A2 (en) * 2000-06-23 2002-01-03 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
CN101186583A (en) * 2007-12-20 2008-05-28 吉林大学 Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application
WO2010115252A1 (en) * 2009-04-06 2010-10-14 Ems S.A. PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-α MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2870130A4 *

Also Published As

Publication number Publication date
SG11201407328TA (en) 2014-12-30
JP2015527309A (en) 2015-09-17
CA2873018A1 (en) 2014-01-09
ZA201408057B (en) 2016-03-30
CN104583162A (en) 2015-04-29
EP2870130A2 (en) 2015-05-13
EP2870130A4 (en) 2015-12-02
WO2014006529A2 (en) 2014-01-09
AU2013285126A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2010007046A3 (en) Heteroaryl derivatives as dgat1 inhibitors
MX2019007713A (en) Compositions and methods for the treatment of chronic pain.
WO2014141057A3 (en) Compositions and methods for the treatment of cancer
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2013168006A3 (en) Compositions and methods for the treatment of local pain
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease
WO2013168004A3 (en) Compositions and methods for the treatment of fibromyalgia pain
MX2021000740A (en) Compositions and methods for the treatment of cancer.
WO2014118649A3 (en) Compositions and methods for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2015519430

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2873018

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2013813543

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013813543

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013285126

Country of ref document: AU

Date of ref document: 20130623

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13813543

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE